Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Public ClinicalTrials.gov record NCT03283826. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical disability, as assessed by confirmed Expanded Disability Status Scale (EDSS) improvement at 12 months in Part 2 in participants with progressive forms of multiple sclerosis (MS) (primary progressive multiple sclerosis \[PPMS\] and secondary progressive multiple sclerosis \[SPMS\]).
Study identification
- NCT ID
- NCT03283826
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 134 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 19, 2017 (Actual)
- Primary completion
- Nov 9, 2023 (Actual)
- Completion
- Jan 17, 2024 (Actual)
- Last update posted
- Feb 23, 2024
2017 – 2024
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Diego | La Jolla | California | 92037 | — |
| Kaiser Permanente MS Clinic Los Angeles | Los Angeles | California | 90027 | — |
| Stanford University | Palo Alto | California | 94304 | — |
| University of California San Francisco | San Francisco | California | 94158 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Advanced Neurology | Fort Collins | Colorado | 80528 | — |
| Neurology Associates, PA-Maitland | Maitland | Florida | 32751 | — |
| University of South Florida, Morsani College of Medicine | Tampa | Florida | 33612 | — |
| Fort Wayne Neurological Center | Fort Wayne | Indiana | 46825 | — |
| University of Kansas Medical Center KUMC - Multiple Sclerosis MS Center | Kansas City | Kansas | 66160 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Dragonfly Research | Wellesley | Massachusetts | 02481 | — |
| Washington University in St. Louis | St Louis | Missouri | 63110 | — |
| Dent Neurologic Institute | Amherst | New York | 14226 | — |
| Columbia University Medical Center-The Neurological Institute of New York | New York | New York | 10032 | — |
| University of Rochester Medical Center - URMC | Rochester | New York | 14642 | — |
| PMG Research of Piedmont Healthcare | Mooresville | North Carolina | 28117 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104-5127 | — |
| Premier Neurology P.C. | Greer | South Carolina | 29650 | — |
| Advanced Neurosciences Institute ANI - Franklin | Franklin | Tennessee | 37064 | — |
| Vanderbilt Comprehensive Multiple Sclerosis Center | Nashville | Tennessee | 37215 | — |
| The University of Texas Health Science Center at Houston | Houston | Texas | 77030 | — |
| MS Center of Greater Washington | Vienna | Virginia | 22182 | — |
| Inland Northwest Research LLC | Spokane | Washington | 99202 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03283826, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 23, 2024 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03283826 live on ClinicalTrials.gov.